<DOC>
	<DOCNO>NCT01745367</DOCNO>
	<brief_summary>This phase 2 multicenter , double-blind , randomize , placebo-controlled , two-arm study subject locally recurrent metastatic triple negative breast cancer . Patients randomize 2:1 either tivozanib hydrochloride weekly paclitaxel placebo weekly paclitaxel . Subjects stratify base Eastern Cooperative Oncology Group ( ECOG ) performance score ( 0 vs 1 ) line treatment ( first v second ) . All subject evaluate progression free survival overall survival well safety tolerability . Biomarker pharmacokinetic ( PK ) analysis also include study . This study determine whether tivozanib hydrocholoride combine weekly paclitaxel improve clinical outcome patient triple negative breast cancer .</brief_summary>
	<brief_title>Tivozanib Hydrochloride Combination With Paclitaxel Versus Placebo With Paclitaxel Patients With Locally Recurrent Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Locally recurrent metastatic TNBC , define ER/PR &lt; 1 % , HER2 01+ , 2+ negative FISH Measurable disease per RECIST version 1.1 ECOG performance status 0 1 Confirmed available archival tumor tissue . More 1 prior systemic chemotherapy treatment locally recurrent metastatic breast cancer ( neoadjuvant adjuvant therapy allow provide subject progress within 12 month taxane base therapy Prior treatment VEGF pathway target agent Major surgery within 4 week minor surgery radiotherapy within 2 week first dose study drug Known history central nervous system metastasis ( subject previously treat ( radiotherapy surgery ) brain metastasis stable steroid enzymeinducing antiepileptic drug least 3 month follow prior treatment may enrol ) Significant hematologic , gastrointestinal , thromboembolic , vascular , bleeding , coagulation disorder Significant serum chemistry urinalysis abnormality Significant cardiovascular disease , include : uncontrolled hypertension ; myocardial infarction unstable angina within 6 month prior administration first dose study drug ; symptomatic leave ventricular dysfunction baseline leave ventricular ejection fraction ( LVEF ) multigated acquisition scan ( MUGA ) ECHO . Severe peripheral neuropathy â‰¥ Grade 2 Currently active second primary malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Tivozanib hydrochloride</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>biomarkers</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>mBC</keyword>
	<keyword>TNBC</keyword>
</DOC>